Clinical trials
Lung Cancer Stage IV clinical trials
Below are recruiting lung cancer stage iv clinical trials, each written for real people, not researchers. We’re tracking 544 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06092086RecruitingPhase 2
Lorlatinib for first-line treatment of ALK-positive lung cancer
This trial tests a targeted pill, lorlatinib, for people with advanced ALK-positive non-small cell lung cancer (NSCLC) who have not received previous treatment for advanced disease. It aims to see how well the drug works in this setting.
Guangzhou, GuangdongAges 18 years+ - NCT04720339Recruiting
Testing blood DNA changes in lung cancer on immunotherapy
This study checks whether tiny bits of tumor DNA in the blood can be measured over time in people with non-small cell lung cancer who are receiving immunotherapy. It aims to see if these blood tests can help track the cancer response or changes during treatment.
BesançonAges 18 years+ - NCT07089199RecruitingPhase 2
Drug combo before surgery for stage III lung cancer
This trial tests a combination of three drugs (tislelizumab, anlotinib, and nab-paclitaxel) given before surgery for stage III lung cancer that can be removed. The goal is to see if this treatment helps shrink the tumor and improves outcomes.
Jinan, ShandongAges 18–75 - NCT06738160RecruitingPhase 2
Combination therapy for bone metastases from advanced lung cancer
This trial tests adding a new drug (narlumosbart) and targeted radiation to standard chemotherapy and immunotherapy for people with advanced non-small cell lung cancer that has spread to the bones. The goal is to see if this combination works better than standard treatment alone.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07058519RecruitingPhase 2
Personalized osimertinib treatment guided by blood test for EGFR lung cancer
This trial tests a personalized treatment plan for advanced lung cancer with an EGFR mutation. It uses a blood test (ctDNA) to guide treatment with osimertinib (a targeted pill) plus chemotherapy. The goal is to see if adjusting therapy based on the blood test results can help you live longer with fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06735391RecruitingPhase 3
JMT101 plus osimertinib vs osimertinib for EGFR-mutant lung cancer
This trial tests a new combination of two targeted drugs (JMT101 and osimertinib) against osimertinib alone for people with advanced lung cancer that has an EGFR mutation. The goal is to see if the combination works better as a first treatment.
GuangzhouAges 18 years+ - NCT07190677Recruiting
Nivolumab plus ipilimumab with chemo for advanced lung cancer
This trial tests combining two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy as a first treatment for advanced lung cancer that has spread or come back. It may help if your cancer hasn't been treated before and doesn't have certain genetic changes.
Pavia, LombardyAges Any age - NCT06517953RecruitingPhase 2
Testing two targeted pills for rare EGFR lung cancer
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
Guangzhou, GuangdongAges 18 years+ - NCT04270591RecruitingPhase 1/Phase 2
Glumetinib for lung cancer with MET changes
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
Louisville, KentuckyAges 18–80 - NCT07638891RecruitingPhase 1
HDM2020 for Advanced Squamous Lung Cancer
This study tests a new drug called HDM2020 in patients with advanced squamous cell lung cancer (a specific type of lung cancer) that has stopped responding to standard treatments. The drug is designed to target cancer cells that have high levels of a specific protein called FGFR2b.
Guangzhou, GuangdongAges 18–75 - NCT07061379Recruiting
Patient feedback in first-line lung cancer treatment study
This study collects patient feedback through questionnaires to see if it helps improve outcomes for people with advanced non-small-cell lung cancer starting chemo-immunotherapy. It may help your care team better understand how you are feeling.
Milan, ItalyAges 18 years+ - NCT05815173RecruitingPhase 1
Ladarixin plus sotorasib for KRAS-mutated lung cancer
This Phase 1 trial tests whether ladarixin combined with sotorasib can help people with advanced or metastatic non-small cell lung cancer (NSCLC) that has a KRAS G12C mutation. It’s mainly testing safety and how well the treatments work after the cancer has progressed despite prior anti–PD-1 treatment.
Garden City, New YorkAges 18–100 - NCT06941948Recruiting
Sleep and immune system in lung cancer
This study looks at how sleep problems affect your body's immune response to lung cancer. It aims to find links between sleep and the tumor environment, which could help improve treatment.
ShanghaiAges 18–70 - NCT06627647RecruitingPhase 3
Comparing two immunotherapy drugs for advanced lung cancer
This trial tests a new immunotherapy drug, rilvegostomig, against the standard pembrolizumab, both given with chemotherapy, as a first treatment for advanced non-squamous non-small cell lung cancer (NSCLC) that cannot be cured with surgery or radiation. It is for people whose tumors have high PD-L1 levels and do not have certain genetic mutations.
Mobile, AlabamaAges 18 years+ - NCT07246863RecruitingPhase 2
Testing visugromab and nivolumab with or without docetaxel for advanced lung cancer
This trial tests a new combination of drugs (visugromab, nivolumab, and possibly docetaxel) for people with advanced non-squamous non-small cell lung cancer that worsened after one prior treatment with an immunotherapy. The goal is to see if the combination helps control the cancer better.
Birmingham, AlabamaAges 18 years+ - NCT06479759RecruitingPhase 2
LM-108 with sintilimab for advanced lung cancer
This trial tests a new antibody combination for non-small cell lung cancer that has spread or come back. It may help people whose cancer stopped responding to immunotherapy or who haven't had treatment yet.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06102928Recruiting
Anlotinib plus Aumolertinib for first-line treatment of advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted drugs (anlotinib and aumolertinib) as the first treatment for advanced lung cancer with a specific EGFR mutation (L858R). The goal is to see if the combination works better than standard care.
Kunming, YunnanAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Chandler, ArizonaAges 18 years+ - NCT03791034Recruiting
Blood DNA test to guide treatment in early lung cancer
This trial studies a “cell-free DNA” blood test to help diagnose and guide treatment decisions for early non-small cell lung cancer. It may help doctors tailor care based on genetic signals seen in the blood before and around surgery.
SeoulAges 18–90 - NCT04136535RecruitingPhase 2
Treating resistant lung cancer with chemo plus or minus an added drug
This Phase 2 study tests whether adding an extra targeted medicine (anlotinib) to standard chemotherapy (pemetrexed and carboplatin) can better control osimertinib-resistant lung cancer with an EGFR mutation. It’s for people whose lung cancer has already progressed after osimertinib, and it aims to shrink tumors and slow the disease.
Shenzhen, shenzhenAges 18–75 - NCT04467723RecruitingPhase 1/Phase 2
Atezolizumab plus pirfenidone for advanced lung cancer
This Phase 1/2 trial tests whether combining atezolizumab and pirfenidone can help people with non-small cell lung cancer (NSCLC) after prior treatment. It is aimed at patients whose cancer has certain genetic markers ruled out and who can safely take study medicines and follow frequent visits.
Fairway, KansasAges 18 years+ - NCT04624373Recruiting
Test tumor DNA from breath biopsy samples
This study checks tiny pieces of DNA from a sample taken during a breathing-tube biopsy (EBUS-TBNA) to better identify certain lung cancer changes. It may help doctors learn more about the type of lung cancer and, in some cases, why targeted treatments stop working.
ToulouseAges 18–65 - NCT04777084RecruitingPhase 2
Lenvatinib plus PD-1 antibody for advanced lung cancer
This Phase 2 study tests whether a combination of lenvatinib and a PD-1/PD-L1–blocking antibody (IBI318) can shrink advanced non-small cell lung cancer and is safe to use. It targets people whose cancer has specific genetic changes or specific prior treatment history, based on three different study groups.
Changsha, HunanAges 18–75 - NCT05339568Recruiting
Smartphone support program for people with advanced lung cancer
This trial tests a “whole process follow-up” care plan, using a smartphone, to support people with non-small cell lung cancer from diagnosis through treatment and follow-up. It may help you manage care steps more smoothly if you’re not a candidate for curative (radical) treatment or don’t want surgery.
Jinan, ShandongAges 18 years+
Hear when a new Lung Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer stage iv?
- Yes. Clin2 currently lists 544 recruiting lung cancer stage iv studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer stage iv trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer stage iv trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.